Display options
Share it on

Iran J Basic Med Sci. 2015 Oct;18(10):974-8.

The vasodilatory action of telmisartan on isolated mesenteric artery rings from rats.

Iranian journal of basic medical sciences

Xiao-Ping Chen, Li-Ren Qian

Affiliations

  1. Department of Hematology, Navy General Hospital of PLA, Beijing, China.

PMID: 26730331 PMCID: PMC4686581

Abstract

OBJECTIVES: Angiotensin II type 1 receptor blockers (ARBs) represent one of the widely used antihypertensive agents. In addition to anti-hypertension effect, some ARBs also show other molecular effects such as activating peroxisome proliferator-activated receptor-γ and so on. Here we studied the effects of telmisartan on the rat isolated mesenteric artery rings pre-contracted by phenylephrine (PE).

MATERIALS AND METHODS: Rat mesenteric artery rings were pre-contracted with 10 μM PE, and cumulative concentration-response curves to telmisartan were obtained. The endothelium-dependent mechanisms were investigated by mechanical removal of the endothelium. K(+) channels were investigated by pretreatment of the artery rings with various K(+) channel blockers.

RESULTS: Telmisartan produced concentration-dependent relaxation of the artery rings pre-contracted by 10 μM PE. Denudation of the endothelium did not affect the relaxant effect of telmisartan. Pretreatment with BaCl2 nearly inhibited the relaxation induced by the 0.5, 1, 5 and 10 μM telmisartan, but did not affect the relaxation induced by the 50 and 100 μM telmisartan. While the relaxation induced by telmisartan was not affected by pretreatment with TEA, 4-AP and glibenclamide.

CONCLUSION: These findings demonstrated that telmisartan produces concentration dependent vasodilation in isolated rat mesenteric artery rings with or without endothelium pre-contracted by PE. KIR channel may be involved in such a relaxant effect of telmisartan.

Keywords: ARB; Mesenteric arteries; Potassium channel; Rat; Telmisartan; Vasodilation

References

  1. N Engl J Med. 1972 Mar 2;286(9):441-9 - PubMed
  2. Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Aug;38(8):751-4 - PubMed
  3. Exp Physiol. 2008 Jan;93(1):141-7 - PubMed
  4. J Int Med Res. 2000 Jul-Aug;28(4):149-67 - PubMed
  5. Am J Respir Cell Mol Biol. 1993 Jan;8(1):1-6 - PubMed
  6. Am J Cardiol. 2006 Jul 1;98(1):121-8 - PubMed
  7. Mol Cell Endocrinol. 2014 Mar 5;383(1-2):60-8 - PubMed
  8. Hypertens Res. 2008 Apr;31(4):601-6 - PubMed
  9. Lancet. 1971 Jul 3;2(7714):19-22 - PubMed
  10. J Pharmacol Exp Ther. 2003 Jun;305(3):846-53 - PubMed
  11. Hypertension. 2004 May;43(5):993-1002 - PubMed
  12. Hypertension. 1992 Aug;20(2):129-37 - PubMed
  13. Cardiovasc Res. 2003 Mar;57(3):824-33 - PubMed
  14. J Smooth Muscle Res. 2008 Apr;44(2):65-81 - PubMed
  15. Curr Hypertens Rep. 2013 Feb;15(1):59-70 - PubMed
  16. Pharmacol Rev. 2013 Mar 13;65(2):809-48 - PubMed
  17. Acta Pharmacol Sin. 2008 Aug;29(8):913-22 - PubMed
  18. Cardiovasc Diabetol. 2013 Jul 19;12:108 - PubMed
  19. Life Sci. 2009 Jan 16;84(3-4):81-8 - PubMed
  20. Hypertension. 2005 Jul;46(1):137-43 - PubMed
  21. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Feb;37(2):165-8 - PubMed

Publication Types